Need help finding what you are looking for?
Contact Us
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1671377
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1671377
HIV Diagnostics Market by Product (Assay Kits & Reagents, Instrument, Software), Test Type (Rapid Test, ELISA, Western Blot, Viral Load, CD4 Test), End User (Diagnostic Laboratories, Homecare Settings, Hospital) - Global Forecast to 2030
PUBLISHED:
PAGES: 274 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global HIV diagnostics market is projected to reach USD 5.31 Billion by 2030 from USD 3.25 Billion in 2025, at a CAGR of 10.3% during the forecast period.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2022-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD) |
| Segments | product, test type, end user, and region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries |
The HIV diagnostics market is driven by several key factors, such as the rising prevalence of HIV/AIDS, the increasing number of blood transfusions and blood donations, advantages offered by POC diagnostic kits & instruments, and the growing focus on initiatives for HIV awareness. However, the high cost of nucleic acid testing, operational barriers, and the shortage of skilled laboratory technicians are expected to restrain the market growth to a certain extent.
Government-led health initiatives and widespread public awareness campaigns encouraging early HIV testing are key drivers of market growth. Additionally, continuous advancements in rapid testing technologies, along with the increasing availability and affordability of self-testing kits, are improving patient compliance and boosting adoption rates. The expansion of diagnostic laboratories, integration of artificial intelligence in diagnostics, and growing collaborations between healthcare organizations and private entities further contribute to market expansion.
However, certain challenges may hinder growth, including the high cost of diagnostic tests, limited access to healthcare in remote regions, and a shortage of skilled professionals to conduct and interpret tests. Regulatory hurdles and concerns regarding the accuracy and reliability of some testing methods also pose potential barriers.
Despite these challenges, the HIV diagnostics market is expected to experience steady growth, driven by increasing awareness, improved healthcare infrastructure, rising government funding for HIV screening programs, and the growing demand for fast, convenient, and highly accurate testing solutions. The increasing focus on early detection and timely intervention, combined with technological innovations in point-of-care testing, is likely to create significant opportunities for market players in the coming years. "The consumables segment accounted for the largest share of the market in 2024, by product."
The HIV diagnostics market is classified by product type into consumables, instruments, and software & services. In 2024, the consumables segment dominated the market, driven by the recurring demand from laboratories and hospitals, the rising prevalence of HIV/AIDS, and government initiatives supporting the development of advanced consumables.
"The confirmatory tests segment accounted for the largest share of the market in 2024, by test type."
By test type, the market is segmented into screening tests, confirmatory tests, and monitoring tests. The monitoring tests segment held the largest share in 2024 and is expected to grow at the highest CAGR. This growth is fueled by increasing awareness of HIV testing, a high volume of monitoring test samples, and the expansion of diagnostic laboratories specializing in HIV/AIDS testing. Additionally, advancements in monitoring test kits are further accelerating the segment's expansion.
"Diagnostic Laboratories segment dominated the HIV diagnostics market in 2024, based on end user."
The HIV diagnostics market is segmented by end users into diagnostic laboratories, hospitals, blood banks, home care settings, and others. In 2024, diagnostic laboratories accounted for the largest market share, driven by the increasing prevalence of HIV/AIDS, the expansion of diagnostic facilities, the rising demand for sample testing, and advancements in point-of-care (POC) technology.
The HIV diagnostics market is segmented into six key regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2024, North America led the global market, driven by factors such as the rising prevalence of HIV/AIDS, advancements in point-of-care (POC) diagnostic instruments and test kits, growing awareness initiatives, and an increase in blood transfusions and donations. The presence of well-established healthcare infrastructure, significant investments in research and development, and supportive government policies further contributed to the region's market dominance.
However, the Asia Pacific region is projected to experience the highest compound annual growth rate during the forecast period. This rapid expansion is fueled by the rising number of HIV cases, the increasing availability of advanced POC diagnostic products, and growing healthcare investments in emerging economies. Additionally, government-led initiatives promoting HIV awareness, improved healthcare accessibility, and a surge in global market players expanding their presence in the region are further accelerating market growth. The region's increasing focus on early disease detection, combined with technological advancements and growing collaborations between public and private healthcare organizations, is expected to create significant opportunities for market expansion.
The break-up of the profile of primary participants in the HIV diagnostics market:
- By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
- By Designation: M-level - 30%, D-level - 50%, and Others - 20%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Others-4%
The key players in this market are are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux SA (France), Hologic, Inc. (US), QIAGEN (Germany), Becton, Dickinson, and Company (US), Trinity Biotech (Ireland), OraSure Technologies (US), BioSynex SA (Chembio Diagnostics) (France), Wondfo (China), Getein Biotech Inc. (China), Meril Diagnostics (India), AccuBioTech (China), BioLytical Laboratories Inc. (Canada), BioLab Diagnostics (India), Alpine Biomedicals Pvt. Ltd (India), Molbio Diagnostics (India), Fortress Diagnostics (UK), AdvaCare Pharma (US), Adaltis s.r.l (Italy) among others.
Research Coverage:
- This research report categorizes the HIV diagnostics market by device type (consumables, instruments, software & services ), by test type (screening tests, confirmatory tests, monitoring tests and other HIV diagnostic tests), by end user (diagnostic laboratories, blood banks, home care settings, hospitals and other endusers), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the HIV diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the HIV diagnostics market. Competitive analysis of upcoming startups in the HIV diagnostics market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall HIV diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Rising prevalence of HIV/AIDS, Increasing number of blood transfusions & blood donations, Advantages offered by POC diagnostic kits & instruments) opportunities (Growth opportunities in emerging economies), restraints (high cost of NATs), and challenges (lack of skilled workforce) influencing the growth of the HIV diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the HIV diagnostics market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the HIV diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HIV diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain).
Product Code: MD 5067
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKET SEGMENTATION
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Primary sources
- 2.1.2.2 Key industry insights
- 2.1.2.3 Key data from primary sources
- 2.1.2.4 Breakdown of primary interviews
- 2.1.1 SECONDARY DATA
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 BOTTOM-UP APPROACH
- 2.2.1.1 Approach 1: Company revenue estimation approach
- 2.2.1.2 Approach 2: Presentations of companies and primary interviews
- 2.2.1.3 Growth forecast
- 2.2.1.4 CAGR projections
- 2.2.2 TOP-DOWN APPROACH
- 2.2.1 BOTTOM-UP APPROACH
- 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
- 2.4 MARKET SHARE ASSUMPTIONS
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 HIV DIAGNOSTICS MARKET OVERVIEW
- 4.2 GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Rising prevalence of HIV/AIDS
- 5.2.1.2 Increasing number of blood transfusions & blood donations
- 5.2.1.3 Advantages offered by POC diagnostic kits & instruments
- 5.2.1.4 Increasing initiatives for HIV awareness campaigns
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of NATs
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 High growth potential of emerging economies
- 5.2.3.2 Trend of self-testing and growing preference for at- home diagnostic kits
- 5.2.4 CHALLENGES
- 5.2.4.1 Operational barriers and shortage of skilled laboratory technicians
- 5.2.1 DRIVERS
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE OF HIV DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2023
- 5.4.2 AVERAGE SELLING PRICE TREND, BY TEST TYPE, 2021-2023
- 5.4.3 AVERAGE SELLING PRICE TREND OF HIV DIAGNOSTIC INSTRUMENTS, BY REGION, 2021-2023 (USD)
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 SUPPLY CHAIN ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 TECHNOLOGY ANALYSIS
- 5.8.1 KEY TECHNOLOGIES
- 5.8.1.1 ELISA
- 5.8.2 COMPLEMENTARY TECHNOLOGIES
- 5.8.2.1 Western blot tests
- 5.8.3 ADJACENT TECHNOLOGIES
- 5.8.3.1 PCR
- 5.8.1 KEY TECHNOLOGIES
- 5.9 INVESTMENT & FUNDING SCENARIO
- 5.10 PATENT ANALYSIS
- 5.11 TRADE ANALYSIS
- 5.11.1 IMPORT DATA FOR HS CODE 3822
- 5.11.2 EXPORT DATA FOR HS CODE 3822
- 5.12 KEY CONFERENCES & EVENTS, 2025-2026
- 5.13 CASE STUDY ANALYSIS
- 5.13.1 ROLE OF COMMUNITY-BASED ORGANIZATIONS (CBOS) IN SUPPORTING PEOPLE WITH HIV
- 5.13.2 MANAGING HIGH BLOOD PRESSURE AND BLOOD SUGAR IN HIV-POSITIVE PATIENTS
- 5.14 REGULATORY LANDSCAPE
- 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.14.2 REGULATORY FRAMEWORK
- 5.14.2.1 North America
- 5.14.2.1.1 US
- 5.14.2.1.2 Canada
- 5.14.2.2 Europe
- 5.14.2.3 Asia Pacific
- 5.14.2.3.1 China
- 5.14.2.3.2 Japan
- 5.14.2.3.3 India
- 5.14.2.4 Latin America
- 5.14.2.4.1 Brazil
- 5.14.2.4.2 Mexico
- 5.14.2.5 Middle East
- 5.14.2.6 Africa
- 5.14.2.1 North America
- 5.15 PORTER'S FIVE FORCES ANALYSIS
- 5.15.1 THREAT OF NEW ENTRANTS
- 5.15.2 THREAT OF SUBSTITUTES
- 5.15.3 BARGAINING POWER OF BUYERS
- 5.15.4 BARGAINING POWER OF SUPPLIERS
- 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.16 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.16.2 KEY BUYING CRITERIA, BY PRODUCT
- 5.17 IMPACT OF AI/GENERATIVE AI ON HIV DIAGNOSTICS MARKET
- 5.17.1 MARKET POTENTIAL OF AI IN HIV DIAGNOSTICS
- 5.17.2 AI USE CASES
- 5.17.3 COMPANY IMPLEMENTATION OF AI
- 5.17.4 FUTURE OF AI/GENERATIVE AI
6 HIV DIAGNOSTICS MARKET, BY TEST TYPE
- 6.1 INTRODUCTION
- 6.2 SCREENING TESTS
- 6.2.1 RAPID TESTS
- 6.2.1.1 Provision of quick test results and ability to diagnose HIV antibodies to fuel uptake
- 6.2.2 ELISA
- 6.2.2.1 Wide applications across infectious disease diagnostics to drive market
- 6.2.3 OTHER SCREENING TESTS
- 6.2.1 RAPID TESTS
- 6.3 CONFIRMATORY TESTS
- 6.3.1 WESTERN BLOT TESTS
- 6.3.1.1 Gold standard testing for result validation to drive market
- 6.3.2 OTHER CONFIRMATORY TESTS
- 6.3.1 WESTERN BLOT TESTS
- 6.4 MONITORING TESTS
- 6.4.1 VIRAL LOAD TESTS
- 6.4.1.1 Accurate provision of quantitative data on HIV infections to boost demand
- 6.4.2 CD4 TESTS
- 6.4.2.1 Ability to number CD4 T lymphocyte cells to support market growth
- 6.4.1 VIRAL LOAD TESTS
- 6.5 OTHER HIV DIAGNOSTIC TESTS
7 HIV DIAGNOSTICS MARKET, BY PRODUCT
- 7.1 INTRODUCTION
- 7.1.1 CONSUMABLES
- 7.1.2 ASSAY KITS & REAGENTS
- 7.1.2.1 Recurrent purchase to fuel market
- 7.1.3 OTHER CONSUMABLES
- 7.2 INSTRUMENTS
- 7.2.1 RISING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
- 7.3 SOFTWARE & SERVICES
- 7.3.1 INCREASING DEMAND FOR VALUE-ADDED SERVICES & AUTOMATED SOFTWARE TO SUPPORT MARKET GROWTH
8 HIV DIAGNOSTICS MARKET, BY END USER
- 8.1 INTRODUCTION
- 8.2 DIAGNOSTIC LABORATORIES
- 8.2.1 HIGH VOLUME OF HIV TESTING SAMPLES TO PROPEL MARKET
- 8.3 HOSPITALS
- 8.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS AND FAVORABLE REIMBURSEMENTS TO DRIVE MARKET
- 8.4 BLOOD BANKS
- 8.4.1 RISING NUMBER OF BLOOD DONATIONS TO BOOST DEMAND
- 8.5 HOME CARE SETTINGS
- 8.5.1 INCREASING PREFERENCE FOR AT-HOME TESTING KITS TO SUPPORT MARKET GROWTH
- 8.6 OTHER END USERS
9 HIV DIAGNOSTICS MARKET, BY REGION
- 9.1 INTRODUCTION
- 9.2 NORTH AMERICA
- 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 9.2.2 US
- 9.2.2.1 High healthcare expenditure to drive market
- 9.2.3 CANADA
- 9.2.3.1 Increasing number of HIV infections and blood donations to drive market
- 9.3 EUROPE
- 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 9.3.2 GERMANY
- 9.3.2.1 Favorable government healthcare policies and reimbursements for HIV testing to drive market
- 9.3.3 UK
- 9.3.3.1 Rising government support for HIV awareness campaigns to support market growth
- 9.3.4 FRANCE
- 9.3.4.1 High prevalence of HIV/AIDS to boost demand
- 9.3.5 ITALY
- 9.3.5.1 Increasing number of blood donors to support market growth
- 9.3.6 SPAIN
- 9.3.6.1 Rising adoption of NAT technology to propel market
- 9.3.7 REST OF EUROPE
- 9.4 ASIA PACIFIC
- 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 9.4.2 CHINA
- 9.4.2.1 Rising incidence of infectious diseases & HIV to propel market
- 9.4.3 JAPAN
- 9.4.3.1 Growing adoption of advanced HIV screening technologies to drive market
- 9.4.4 INDIA
- 9.4.4.1 Government initiatives such as free HIV testing to drive market
- 9.4.5 REST OF ASIA PACIFIC
- 9.5 LATIN AMERICA
- 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 9.5.2 BRAZIL
- 9.5.2.1 Increasing uptake of technologically advanced blood screening tests to drive market
- 9.5.3 MEXICO
- 9.5.3.1 Rising establishment of blood banks to support market growth
- 9.5.4 REST OF LATIN AMERICA
- 9.6 MIDDLE EAST & AFRICA
- 9.6.1 RISING NUMBER OF HIV DIAGNOSTICS AND SURGICAL PROCEDURES TO FUEL MARKET
- 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 9.7 GCC COUNTRIES
- 9.7.1 RISING FOCUS ON HIV TESTING AND IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
- 9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
10 COMPETITIVE LANDSCAPE
- 10.1 OVERVIEW
- 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HIV DIAGNOSTICS MARKET
- 10.3 REVENUE ANALYSIS, 2021-2023
- 10.4 MARKET SHARE ANALYSIS, 2023
- 10.4.1 RANKING OF KEY MARKET PLAYERS
- 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 10.5.1 STARS
- 10.5.2 EMERGING LEADERS
- 10.5.3 PERVASIVE PLAYERS
- 10.5.4 PARTICIPANTS
- 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 10.5.5.1 Company footprint
- 10.5.5.2 Region footprint
- 10.5.5.3 Product footprint
- 10.5.5.4 End-user footprint
- 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 10.6.1 PROGRESSIVE COMPANIES
- 10.6.2 RESPONSIVE COMPANIES
- 10.6.3 DYNAMIC COMPANIES
- 10.6.4 STARTING BLOCKS
- 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 10.6.5.1 Detailed list of key startups/SME players
- 10.6.5.2 Competitive benchmarking of key startups/SMEs
- 10.7 COMPANY VALUATION & FINANCIAL METRICS
- 10.8 BRAND/PRODUCT COMPARISON
- 10.9 COMPETITIVE SCENARIO
- 10.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
- 10.9.2 PRODUCT LAUNCHES & APPROVALS
- 10.9.3 DEALS
- 10.9.4 EXPANSIONS
- 10.9.5 OTHER DEVELOPMENTS
11 COMPANY PROFILES
- 11.1 KEY PLAYERS
- 11.1.1 ABBOTT
- 11.1.1.1 Business overview
- 11.1.1.2 Products/Services offered
- 11.1.1.3 Recent developments
- 11.1.1.3.1 Deals
- 11.1.1.4 MnM view
- 11.1.1.4.1 Key strengths
- 11.1.1.4.2 Strategic choices
- 11.1.1.4.3 Weaknesses & competitive threats
- 11.1.2 SIEMENS HEALTHINEERS
- 11.1.2.1 Business overview
- 11.1.2.2 Products/Services offered
- 11.1.2.3 Recent developments
- 11.1.2.3.1 Product/Service launches & approvals
- 11.1.2.3.2 Deals
- 11.1.2.3.3 Other developments
- 11.1.2.4 MnM view
- 11.1.2.4.1 Key strengths
- 11.1.2.4.2 Strategic choices
- 11.1.2.4.3 Weaknesses & competitive threats
- 11.1.3 GRIFOLS, S.A.
- 11.1.3.1 Business overview
- 11.1.3.2 Products/Services offered
- 11.1.3.3 Recent developments
- 11.1.3.3.1 Deals
- 11.1.3.4 MnM view
- 11.1.3.4.1 Key strengths
- 11.1.3.4.2 Strategic choices
- 11.1.3.4.3 Weaknesses & competitive threats
- 11.1.4 DANAHER CORPORATION
- 11.1.4.1 Business overview
- 11.1.4.2 Products/Services offered
- 11.1.4.3 Recent developments
- 11.1.4.3.1 Product launches & approvals
- 11.1.4.3.2 Deals
- 11.1.4.3.3 Expansions
- 11.1.4.4 MnM view
- 11.1.4.4.1 Key strengths
- 11.1.4.4.2 Strategic choices
- 11.1.4.4.3 Weaknesses & competitive threats
- 11.1.5 THERMO FISHER SCIENTIFIC INC.
- 11.1.5.1 Business overview
- 11.1.5.2 Products/Services offered
- 11.1.5.3 Recent developments
- 11.1.5.3.1 Product/Service launches & approvals
- 11.1.5.3.2 Deals
- 11.1.5.4 MnM view
- 11.1.5.4.1 Key strengths
- 11.1.5.4.2 Strategic choices
- 11.1.5.4.3 Weaknesses & competitive threats
- 11.1.6 BIO-RAD LABORATORIES, INC.
- 11.1.6.1 Business overview
- 11.1.6.2 Products/Services offered
- 11.1.6.2.1 Deals
- 11.1.7 F. HOFFMANN-LA ROCHE LTD.
- 11.1.7.1 Business overview
- 11.1.7.2 Products/Services offered
- 11.1.7.3 Recent developments
- 11.1.7.3.1 Product launches & approvals
- 11.1.7.3.2 Deals
- 11.1.7.3.3 Expansions
- 11.1.1 ABBOTT
- 11.2 OTHER PLAYERS
- 11.2.1 BIOMERIEUX
- 11.2.2 HOLOGIC, INC.
- 11.2.3 QIAGEN
- 11.2.4 BD
- 11.2.5 TRINITY BIOTECH
- 11.2.6 ORASURE TECHNOLOGIES, INC.
- 11.2.7 BIOSYNEX SA
- 11.2.8 WONDFO
- 11.2.9 GETEIN BIOTECH, INC.
- 11.2.10 MERIL LIFE SCIENCES PVT. LTD.
- 11.2.11 ACCUBIOTECH CO., LTD.
- 11.2.12 BIOLYTICAL LABORATORIES INC.
- 11.2.13 BIO LAB DIAGNOSTICS (I) PRIVATE LIMITED
- 11.2.14 ALPINE BIOMEDICALS PVT LTD.
- 11.2.15 MOLBIO DIAGNOSTICS PVT. LTD.
- 11.2.16 FORTRESS DIAGNOSTICS
- 11.2.17 ADVACARE PHARMA (ACCUQUIK)
- 11.2.18 ADALTIS S.R.L.
12 APPENDIX
- 12.1 DISCUSSION GUIDE
- 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 12.3 CUSTOMIZATION OPTIONS
- 12.4 RELATED REPORTS
- 12.5 AUTHOR DETAILS
Product Code: MD 5067
List of Tables
- TABLE 1 HIV DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
- TABLE 2 HIV DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
- TABLE 3 NUMBER OF PEOPLE LIVING WITH HIV VS. NEW HIV CASES, BY REGION (2023)
- TABLE 4 AVERAGE SELLING PRICE OF HIV DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2023
- TABLE 5 AVERAGE SELLING PRICE TREND, BY TEST TYPE, 2021-2023
- TABLE 6 AVERAGE SELLING PRICE TREND OF HIV DIAGNOSTIC INSTRUMENTS, BY REGION, 2021-2023 (USD)
- TABLE 7 HIV DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
- TABLE 8 HIV DIAGNOSTICS MARKET: INNOVATIONS & PATENT REGISTRATIONS, 2023-2024
- TABLE 9 IMPORT DATA FOR HS CODE 9021, BY COUNTRY, 2019-2023 (USD MILLION)
- TABLE 10 EXPORT DATA FOR HS CODE 9021, BY COUNTRY, 2019-2023 (USD MILLION)
- TABLE 11 HIV DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025-2026
- TABLE 12 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 15 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 16 EUROPE: CLASSIFICATION OF DEVICES
- TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
- TABLE 18 HIV DIAGNOSTICS MARKET: PORTER'S FIVE FORCES
- TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%)
- TABLE 20 KEY BUYING CRITERIA FOR PRODUCTS, BY RANK
- TABLE 21 COMPANY IMPLEMENTATION OF AI IN HIV DIAGNOSTICS MARKET
- TABLE 22 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 23 US: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (MILLION TESTS)
- TABLE 24 US: HIV DIAGNOSTICS MARKET, BY RAPID TEST TYPE, 2022-2030 (MILLION TESTS)
- TABLE 25 US: HIV DIAGNOSTICS MARKET, BY CONFIRMATORY TEST TYPE, 2022-2030 (MILLION TESTS)
- TABLE 26 HIV DIAGNOSTICS MARKET FOR SCREENING TESTS, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 27 SCREENING TESTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 28 NORTH AMERICA: SCREENING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 29 EUROPE: SCREENING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 30 ASIA PACIFIC: SCREENING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 31 LATIN AMERICA: SCREENING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 32 RAPID TESTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 33 NORTH AMERICA: RAPID TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 34 EUROPE: RAPID TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 35 ASIA PACIFIC: RAPID TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 36 LATIN AMERICA: RAPID TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 37 ELISA MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 38 NORTH AMERICA: ELISA MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 39 EUROPE: ELISA MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 40 ASIA PACIFIC: ELISA MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 41 LATIN AMERICA: ELISA MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 42 OTHER SCREENING TESTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 43 NORTH AMERICA: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 44 EUROPE: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 45 ASIA PACIFIC: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 46 LATIN AMERICA: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 47 CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 48 CONFIRMATORY TESTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 49 NORTH AMERICA: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 50 EUROPE: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 51 ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 52 LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 53 WESTERN BLOT TESTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 54 NORTH AMERICA: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 55 EUROPE: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 56 ASIA PACIFIC: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 57 LATIN AMERICA: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 58 OTHER CONFIRMATORY TESTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 59 NORTH AMERICA: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 60 EUROPE: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 61 ASIA PACIFIC: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 62 LATIN AMERICA: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 63 MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 64 MONITORING TESTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 65 NORTH AMERICA: MONITORING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 66 EUROPE: MONITORING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 67 ASIA PACIFIC: MONITORING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 68 LATIN AMERICA: MONITORING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 69 VIRAL LOAD TESTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 70 NORTH AMERICA: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 71 EUROPE: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 72 ASIA PACIFIC: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 73 LATIN AMERICA: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 74 CD4 TESTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 75 NORTH AMERICA: CD4 TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 76 EUROPE: CD4 TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 77 ASIA PACIFIC: CD4 TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 78 LATIN AMERICA: CD4 TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 79 OTHER HIV DIAGNOSTIC TESTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 80 NORTH AMERICA: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 81 EUROPE: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 82 ASIA PACIFIC: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 83 LATIN AMERICA: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 84 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 85 HIV DIAGNOSTICS MARKET FOR CONSUMABLES MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 86 HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2022-2030 (USD MILLION)
- TABLE 87 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 88 EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 89 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 90 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 91 ASSAY KITS & REAGENTS OFFERED BY KEY PLAYERS
- TABLE 92 ASSAY KITS & REAGENTS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 93 NORTH AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 94 EUROPE: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 95 ASIA PACIFIC: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 96 LATIN AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 97 OTHER CONSUMABLES MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 98 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 99 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 100 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 101 LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 102 KEY INSTRUMENTS AVAILABLE IN HIV DIAGNOSTICS MARKET
- TABLE 103 HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022-2030 (USD MILLION)
- TABLE 104 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 105 EUROPE: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 106 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 107 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 108 HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2022-2030 (USD MILLION)
- TABLE 109 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 110 EUROPE: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 111 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 112 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 113 HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 114 DIAGNOSTIC LABORATORIES MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 115 NORTH AMERICA: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 116 EUROPE: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 117 ASIA PACIFIC: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 118 LATIN AMERICA: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 119 HOSPITALS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 120 NORTH AMERICA: HOSPITALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 121 EUROPE: HOSPITALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 122 ASIA PACIFIC: HOSPITALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 123 LATIN AMERICA: HOSPITALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 124 BLOOD BANKS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 125 NORTH AMERICA: BLOOD BANKS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 126 EUROPE: BLOOD BANKS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 127 ASIA PACIFIC: BLOOD BANKS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 128 LATIN AMERICA: BLOOD BANKS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 129 HOME CARE SETTINGS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 130 NORTH AMERICA: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 131 EUROPE: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 132 ASIA PACIFIC: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 133 LATIN AMERICA: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 134 OTHER END USERS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 135 NORTH AMERICA: OTHER END USERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 136 EUROPE: OTHER END USERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 137 ASIA PACIFIC: OTHER END USERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 138 LATIN AMERICA: OTHER END USERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 139 HIV DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
- TABLE 140 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 141 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 142 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 143 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 144 NORTH AMERICA: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 145 NORTH AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 146 NORTH AMERICA: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 147 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 148 US: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 149 US: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 150 US: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 151 US: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 152 US: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 153 US: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 154 US: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 155 CANADA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 156 CANADA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 157 CANADA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 158 CANADA: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 159 CANADA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 160 CANADA: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 161 CANADA: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 162 EUROPE: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 163 EUROPE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 164 EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 165 EUROPE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 166 EUROPE: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 167 EUROPE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 168 EUROPE: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 169 EUROPE: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 170 GERMANY: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 171 GERMANY: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 172 GERMANY: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 173 GERMANY: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 174 GERMANY: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 175 GERMANY: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 176 GERMANY: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 177 UK: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 178 UK: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 179 UK: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 180 UK: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 181 UK: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 182 UK: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 183 UK: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 184 FRANCE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 185 FRANCE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 186 FRANCE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 187 FRANCE: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 188 FRANCE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 189 FRANCE: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 190 FRANCE: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 191 ITALY: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 192 ITALY: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 193 ITALY: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 194 ITALY: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 195 ITALY: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 196 ITALY: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 197 ITALY: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 198 SPAIN: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 199 SPAIN: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 200 SPAIN: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 201 SPAIN: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 202 SPAIN: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 203 SPAIN: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 204 SPAIN: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 205 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 206 REST OF EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 207 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 208 REST OF EUROPE: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 209 REST OF EUROPE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 210 REST OF EUROPE: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 211 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 212 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 213 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 214 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 215 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 216 ASIA PACIFIC: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 217 ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 218 ASIA PACIFIC: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 219 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 220 CHINA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 221 CHINA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 222 CHINA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 223 CHINA: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 224 CHINA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 225 CHINA: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 226 CHINA: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 227 JAPAN: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 228 JAPAN: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 229 JAPAN: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 230 JAPAN: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 231 JAPAN: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 232 JAPAN: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 233 JAPAN: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 234 INDIA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 235 INDIA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 236 INDIA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 237 INDIA: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 238 INDIA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 239 INDIA: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 240 INDIA: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 241 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 242 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 243 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 244 REST OF ASIA PACIFIC: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 245 REST OF ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 246 REST OF ASIA PACIFIC: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 247 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 248 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
- TABLE 249 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 250 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 251 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 252 LATIN AMERICA: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 253 LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 254 LATIN AMERICA: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 255 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 256 BRAZIL: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 257 BRAZIL: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 258 BRAZIL: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 259 BRAZIL: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 260 BRAZIL: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 261 BRAZIL: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 262 BRAZIL HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 263 MEXICO: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 264 MEXICO: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 265 MEXICO: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 266 MEXICO: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 267 MEXICO: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 268 MEXICO: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 269 MEXICO: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 270 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 271 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 272 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 273 REST OF LATIN AMERICA: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 274 REST OF LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 275 REST OF LATIN AMERICA: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 276 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 277 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 278 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 279 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 280 MIDDLE EAST & AFRICA: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 281 MIDDLE EAST & AFRICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 282 MIDDLE EAST & AFRICA: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 283 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 284 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
- TABLE 285 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
- TABLE 286 GCC COUNTRIES: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 287 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
- TABLE 288 GCC COUNTRIES: SCREENING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 289 GCC COUNTRIES: CONFIRMATORY TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 290 GCC COUNTRIES: MONITORING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
- TABLE 291 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
- TABLE 292 GCC COUNTRIES: MACROECONOMIC INDICATORS
- TABLE 293 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HIV DIAGNOSTICS MARKET
- TABLE 294 HIV DIAGNOSTICS MARKET: DEGREE OF COMPETITION
- TABLE 295 HIV DIAGNOSTICS MARKET: REGION FOOTPRINT
- TABLE 296 HIV DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
- TABLE 297 HIV DIAGNOSTICS MARKET: END-USER FOOTPRINT
- TABLE 298 HIV DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
- TABLE 299 HIV DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
- TABLE 300 HIV DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2025
- TABLE 301 HIV DIAGNOSTICS MARKET: DEALS, JANUARY 2021-MARCH 2025
- TABLE 302 HIV DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021-MARCH 2025
- TABLE 303 HIV DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2025
- TABLE 304 ABBOTT: COMPANY OVERVIEW
- TABLE 305 ABBOTT: PRODUCTS/SERVICES OFFERED
- TABLE 306 ABBOTT: DEALS, JANUARY 2021-JANUARY 2025
- TABLE 307 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
- TABLE 308 GRIFOLS, S.A.: COMPANY OVERVIEW
- TABLE 309 GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED
- TABLE 310 GRIFOLS, S.A.: DEALS, JANUARY 2021- JANUARY 2025
- TABLE 311 DANAHER: COMPANY OVERVIEW
- TABLE 312 DANAHER: PRODUCTS/SERVICES OFFERED
- TABLE 313 DANAHER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JANUARY 2025
- TABLE 314 DANAHER: DEALS, JANUARY 2021-JANUARY 2025
- TABLE 315 DANAHER: EXPANSIONS, JANUARY 2021-JANUARY 2025
- TABLE 316 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
- TABLE 317 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
- TABLE 318 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JANUARY 2025
- TABLE 319 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-JANUARY 2025
- TABLE 320 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
- TABLE 321 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
- TABLE 322 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021- JANUARY 2025
- TABLE 323 F. HOFFMANN-LA ROCHE LTD..: COMPANY OVERVIEW
- TABLE 324 F. HOFFMANN-LA ROCHE LTD..: PRODUCTS/SERVICES OFFERED
- TABLE 325 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JANUARY 2025
- TABLE 326 F. HOFFMANN-LA ROCHE LTD..: DEALS, JANUARY 2021- JANUARY 2025
- TABLE 327 F. HOFFMANN-LA ROCHE LTD..: EXPANSIONS, JANUARY 2021- JANUARY 2025
- TABLE 328 BD: COMPANY OVERVIEW
- TABLE 329 TRINITY BIOTECH: COMPANY OVERVIEW
- TABLE 330 BIOSYNEX SA: COMPANY OVERVIEW
- TABLE 331 GETEIN BIOTECH, INC.: COMPANY OVERVIEW
- TABLE 332 ADALTIS S.R.L.: COMPANY OVERVIEW
List of Figures
- FIGURE 1 MARKETS & REGIONS COVERED
- FIGURE 2 HIV DIAGNOSTICS MARKET: RESEARCH DESIGN
- FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
- FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
- FIGURE 6 HIV DIAGNOSTICS MARKET: TOP-DOWN APPROACH
- FIGURE 7 DATA TRIANGULATION METHODOLOGY
- FIGURE 8 HIV DIAGNOSTICS MARKET: STUDY ASSUMPTIONS
- FIGURE 9 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
- FIGURE 10 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION)
- FIGURE 11 HIV DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
- FIGURE 12 HIV DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
- FIGURE 13 INCREASING PREVALENCE OF HIV AND RISING BLOOD DONATIONS TO PROPEL MARKET
- FIGURE 14 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
- FIGURE 15 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION)
- FIGURE 16 HIV DIAGNOSTICS SCREENING TESTS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
- FIGURE 17 HIV DIAGNOSTICS CONFIRMATORY TESTS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
- FIGURE 18 HIV DIAGNOSTICS MONITORING TESTS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
- FIGURE 19 HIV DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
- FIGURE 20 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
- FIGURE 21 HIV DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 22 NEW REVENUE POCKETS FOR PLAYERS IN HIV DIAGNOSTICS MARKET
- FIGURE 23 HIV DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
- FIGURE 24 HIV DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
- FIGURE 25 HIV DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
- FIGURE 26 INVESTMENT & FUNDING SCENARIO, 2018-2025
- FIGURE 27 HIV DIAGNOSTICS MARKET: PATENT ANALYSIS, JANUARY 2014-DECEMBER 2024
- FIGURE 28 HIV DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
- FIGURE 30 KEY BUYING CRITERIA, BY PRODUCT
- FIGURE 31 MARKET POTENTIAL OF AI IN HIV DIAGNOSTICS
- FIGURE 32 HIV DIAGNOSTICS MARKET SEGMENTATION, BY PRODUCT
- FIGURE 33 NORTH AMERICA: HIV DIAGNOSTICS MARKET SNAPSHOT
- FIGURE 34 ASIA PACIFIC: HIV DIAGNOSTICS MARKET SNAPSHOT
- FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET, 2021-2023 (USD MILLION)
- FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET (2023)
- FIGURE 37 RANKING OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET, 2023
- FIGURE 38 HIV DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
- FIGURE 39 HIV DIAGNOSTICS MARKET: COMPANY FOOTPRINT
- FIGURE 40 HIV DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
- FIGURE 41 EV/EBITDA OF KEY VENDORS
- FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 43 HIV DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
- FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2023)
- FIGURE 45 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023)
- FIGURE 46 GRIFOLS, S.A.: COMPANY SNAPSHOT (2023)
- FIGURE 47 DANAHER: COMPANY SNAPSHOT (2023)
- FIGURE 48 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
- FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
- FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.